Badanie nad barzolvolimabem u pacjentów z przewlekłą pokrzywką samoistną, którzy nie reagują na leczenie lekami przeciwhistaminowymi H1

Chronic Spontaneous Urticaria is a condition where people experience itchy hives and sometimes swelling without a known cause. This study is looking at a new treatment called barzolvolimab to see if it can help people with this condition who still have symptoms despite taking H1 antihistamines, which are common allergy medications. The study will compare the effects of barzolvolimab to a placebo, which looks like the real treatment but doesn't contain the active medicine.

The main goal of the study is to see if barzolvolimab can reduce the activity of the urticaria, which is measured by a score called the UAS7. This score helps doctors understand how severe the hives are over a week. Participants in the study will receive either barzolvolimab or a placebo and will be monitored to see how their symptoms change over time. The study will last for several weeks, and the main results will be checked at Week 12.

During the study, participants will continue their usual antihistamine treatment and will be asked to keep a daily diary of their symptoms. This will help researchers understand how well the new treatment works compared to the placebo. The study aims to provide more information on whether barzolvolimab can be a helpful option for people with Chronic Spontaneous Urticaria who do not get enough relief from current treatments.